drugset / Trial / NCT06932757
Adjuvant Quisinostat in High-Risk Uveal Melanoma
Phase 2
Recruiting
63 enrolled
University of Miami
Joseph and Florence Mandel Family Foundation · collabViriom · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Timeline
- Start
- 2025-05-27
- Primary completion
- 2030-05-27
- Completion
- 2030-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quisinostat | Small molecule | 12 mg | Oral |